Cambrian Bio will present new ATX-304 metabolic data at ObesityWeek 2026. See how AMPK activation could influence future obesity treatment.
Insulet launches Omnipod Discover across the US after 15,000 users adopt the platform. Examine its glucose data, clinical evidence and impact.
Precision Diabetes and Nagase Diagnostics target wider U.S. access for Lucica, an FDA-cleared assay for two-to-three-week glycemic monitoring.
UpDoc is moving patient-facing artificial intelligence beyond reminders and administrative support into insulin management. Its narrow FDA clearance, physician-defined limits and early clinical evidence reveal both the potential and the boundaries of autonomous chronic-disease care.
AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.
Find out how Insulet’s Omnipod 6 and fully closed-loop data could reshape automated insulin delivery for diabetes care.
Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.
Find out how Dexcom G7 data could reshape CGM adoption for type 2 diabetes patients not using insulin.
Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.
Cirius Therapeutics is pushing CIR-0602K into the ADA 2026 spotlight. Find out why insulin sensitivity may be diabetes’ next battleground.